Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease

Chest

Volumn 136, Issue 4, 2009, Pages 1101-1111

  Gómez Puerta, Jose A ^a   Hernández Rodríguez, José ^a   López Soto, Alfonso ^a   Bosch, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATALITY; GLOMERULONEPHRITIS; GRANULOMA; GRANULOMATOUS VASCULITIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LUNG COMPLICATION; LUNG HEMORRHAGE; MICROSCOPIC POLYANGIITIS; NECROTIC GLOMERULONEPHRITIS; NECROTIZING GRANULOMATOUS VASCULITIS; NECROTIZING PULMONARY CAPILLARITIS; NEOPLASM; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RENAL VASCULITIS; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMIC DISEASE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 70350111167     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-3043     Document Type: Article

References (98)

1. Rosen MJ. Dr. Friedrich Wegener, the ACCP, and history. Chest 2007; 132:739-741
2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192 (Pubitemid 24065492)
3. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368:404-418
4. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus 1998; 7:238-258 (Pubitemid 28264002)
5. Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87:4115-4119
6. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006; 17:1235-1242 (Pubitemid 43673403)
7. Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr Opin Rheumatol 2007; 19:17-24 (Pubitemid 44885722)
8. Schreiber A, Busjahn A, Luft FC, et al. Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14:68-75 (Pubitemid 36026298)
9. Tse WY, Nash GB, Hewins P, et al. ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation. Kidney Int 2005; 67:130-139 (Pubitemid 40019234)
10. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006; 2:661-670 (Pubitemid 44830855)
11. Day CJ, Hewins P, Savage CO. New developments in the pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol 2003; 21:S35-S48 (Pubitemid 38016478)
12. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963
13. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106:2050-2058 (Pubitemid 41291719)
14. Foucher P, Heeringa P, Petersen AH, et al. Antimyeloperoxidase-associated lung disease: an experimental model. Am J Respir Crit Care Med 1999; 160:987-994 (Pubitemid 29442041)
15. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352:330-332
16. Sarraf P, Sneller MC. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev Mol Med 2005; 7:1-19 (Pubitemid 43118231)
17. Voswinkel J, Muller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005; 1051:12-19 (Pubitemid 41362728)
18. Lamprecht P, Mueller A, Gross WL. CD28-T cells display features of effector memory T cells in Wegener's granulomatosis [letter]. Kidney Int 2004; 65:1113
19. Komocsi A, Lamprecht P, Csernok E, et al. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon- and tumor necrosis factor-α in Wegener's granulomatosis. Am J Pathol 2002; 160:1717-1724 (Pubitemid 34525651)
20. Csernok E, Trabandt A, Muller A, et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999; 42:742-750 (Pubitemid 29171995)
21. Abdulahad WH, Stegeman CA, Limburg PC, et al. CD4- positive effector memory T cells participate in disease expression in ANCA-associated vasculitis. Ann N Y Acad Sci 2007; 1107:22-31
22. Voswinkel J, Mueller A, Kraemer JA, et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65:859-864
23. Preston GA, Pendergraft WF III, Falk RJ. New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr Opin Nephrol Hypertens 2005; 14:217-222
24. Eisenberger U, Fakhouri F, Vanhille P, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20:1392-1399 (Pubitemid 41430612)
25. Cunningham MA, Huang XR, Dowling JP, et al. Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J Am Soc Nephrol 1999; 10:499-506
26. Carrie S, Fenton PA. Necrobacillosis: an unusual case of pharyngotonsillitis. J Laryngol Otol 1994; 108:1097-1098
27. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2008; 68:310-317
28. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14:1088-1096
29. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498
30. Polychronopoulos VS, Prakash UB, Golbin JM, et al. Airway involvement in Wegener's granulomatosis. Rheum Dis Clin North Am 2007; 33:755-775, vi
31. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25-32
32. Bosch X, Lopez-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 1994; 118:517-522 (Pubitemid 24176829)
33. Guillevin L, Pagnoux C, Mahr A, et al. The Five-Factor Score (FFS) revisited: a tool to assess the prognoses of polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS) and Wegener's granulomatosis (WG) based on 1108 patients from the French Vasculitis Study Group (FVSG) [abstract]. Arthritis Rheum 2008; 58(suppl):S906
34. Nada AK, Torres VE, Ryu JH, et al. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990; 65:847-856
35. Gaudin PB, Askin FB, Falk RJ, et al. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and antimyeloperoxidase. Am J Clin Pathol 1995; 104:7-16
36. Gómez-Puerta J, Espinosa G, Morla R, et al. Pulmonary alveolitis as a presenting manifestation of microscopic polyangiitis successfully treated with mycophenolate mofetil. Clin Exp Rheumatol 2009; 27:166-167
37. Luqmani RA, Flossmann O. Outcome in small-vessel systemic vasculitis. J Rheumatol 2006; 33:1224-1227
38. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44 (Pubitemid 36765101)
39. Langford CA. Treatment of ANCA-associated vasculitis. N Engl J Med 2003; 349:3-4
40. Booth A, Harper L, Hammad T, et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721 (Pubitemid 38294802)
41. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 2006; 18:25-32
42. Bosch X, Guilabert A, Espinosa G, et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007; 298:655-669 (Pubitemid 47236417)
43. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58:2908-2918
44. Chen M, Yu F, Zhang Y, et al. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 2008; 87:203-209
45. Holguin F, Ramadan B, Gal AA, et al. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci 2008; 336:321-326
46. Khan SA, Subla MR, Behl D, et al. Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 2007; 131:972-976 (Pubitemid 46608694)
47. Guillevin L, Le Thi Huong D, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg- Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988; 27:258-264 (Pubitemid 18196556)
48. Stegeman CA, Tervaert JW, de Jong PE, et al. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis: Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16-20
49. Iwatani H, Uzu T, Kakihara M, et al. A case of Wegener's granulomatosis with pulmonary bleeding successfully treated with double filtration plasmapheresis (DFPP). Clin Exp Nephrol 2004; 8:369-374 (Pubitemid 40941116)
50. Sugimoto T, Deji N, Kume S, et al. Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener's granulomatosis effectively treated with early plasma exchange therapy. Intern Med 2007; 46:49-53 (Pubitemid 46062253)
51. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188 (Pubitemid 47041083)
52. Heslet L, Nielsen JD, Levi M, et al. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care 2006; 10:R177 (Pubitemid 46211017)
53. Betensley AD, Yankaskas JR. Factor VIIa for alveolar hemorrhage in microscopic polyangiitis. Am J Respir Crit Care Med 2002; 166:1291-1292 (Pubitemid 35222610)
54. Hoffman GS, Thomas-Golbanov CK, Chan J, et al. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003; 30:1017-1021 (Pubitemid 36529623)
55. Solans-Laque R, Bosch-Gil J, Canela M, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Lupus 2008; 17:832-836
56. Sarraf P, Kay J, Friday RP, et al. Wegener's granulomatosis: is biologic therapy useful? Curr Rheumatol Rep 2006; 8:303-311
57. Noronha IL, Kruger C, Andrassy K, et al. In situ production of TNF-α, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993; 43:682-692
58. Huugen D, Xiao H, van Esch A, et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am J Pathol 2005; 167:47-58 (Pubitemid 40884769)
59. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608-1618
60. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-1307 (Pubitemid 35363806)
61. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109:1718-1723 (Pubitemid 38500672)
62. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNFα blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61:559 (Pubitemid 34539105)
63. Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008; 67:1343-1346
64. Seymour MW, Home DM, Williams RO, et al. Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis. Rheumatology (Oxford) 2007; 46:1738-1739
65. Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007; 26:1353-1355 (Pubitemid 47034197)
66. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005; 24:304-307 (Pubitemid 41582342)
67. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44:2836-2840 (Pubitemid 34016203)
68. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187
69. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970-2982
70. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-858
71. Brihaye B, Aouba A, Pagnoux C, et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25:S23-S27 (Pubitemid 46656590)
72. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35:2017-2023
73. Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45:1432-1436 (Pubitemid 44605482)
74. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43:315-320 (Pubitemid 38313180)
75. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1087-1091 (Pubitemid 47050609)
76. Lin S, Shan L, Mingcai Q. A case of Wegener's granulomatosis treated with mycophenolate mofetil. Nephron 2002; 92:959 (Pubitemid 36151391)
77. Waiser J, Budde K, Braasch E, et al. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 1999; 34:e9
78. Joy MS, Hogan SL, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20:2725-2732
79. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66:798-802
80. Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23:1307-1312 (Pubitemid 351767500)
81. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278-283 (Pubitemid 38468715)
82. Nowack R, Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10:1965-1971 (Pubitemid 29402518)
83. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65:1440-1448 (Pubitemid 38406986)
84. Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009; 1125-1130
85. Tatsis E, Schnabel A, Gross WL. Interferon-α treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129:370-374 (Pubitemid 28402791)
86. Simon HU, Seelbach H, Ehmann R, et al. Clinical and immunological effects of low-dose IFN-α treatment in patients with corticosteroid-resistant asthma. Allergy 2003; 58:1250-1255 (Pubitemid 37487181)
87. Termeer CC, Simon JC, Schopf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 2001; 137:136-138 (Pubitemid 32163661)
88. Lamprecht P, Till A, Steinmann J, et al. Current state of biologicals in the management of systemic vasculitis. Ann N Y Acad Sci 2007; 1110:261-270 (Pubitemid 350043015)
89. Nagashima M, Matsushima M, Matsuoka H, et al. High-dose gammaglobulin therapy for Kawasaki disease. J Pediatr 1987; 110:710-712 (Pubitemid 17074737)
90. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35:1150-1153 (Pubitemid 126719653)
91. Levy Y, George J, Fabbrizzi F, et al. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J 1999; 92:412-414 (Pubitemid 29197496)
92. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433-439 (Pubitemid 30459921)
93. Abdou NI, Kullman GJ, Hoffman GS, et al. Wegener's granulomatosis: survey of 701 patients in North America: changes in outcome in the 1990s. J Rheumatol 2002; 29:309-316
94. Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564-567
95. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632-638 (Pubitemid 41552527)
96. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25:492-495 (Pubitemid 28109351)
97. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361
98. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendation. Available at: http://www.cebm.net/levels-of-evidence.asp. Accessed May 21, 2007